BioXcel Therapeutics (BTAI) Other Operating Expenses (2022 - 2026)

BioXcel Therapeutics' Other Operating Expenses history runs 5 years deep, the most recent figure standing at $283000.0 for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 1921.43% year-over-year to $283000.0; the TTM figure through Mar 2026 stood at $433000.0 (down 79.15% YoY), while the FY2025 annual figure was $164000.0, down 92.35% from the prior year.
• Other Operating Expenses was $283000.0 for Q1 2026 at BioXcel Therapeutics, up from $32000.0 in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $1.2 million in Q3 2024 to a low of $9000.0 in Q4 2022.
• Historically, Other Operating Expenses has averaged $258066.7 across 5 years, with a median of $62000.0 in 2024.
• The sharpest annual moves came in 2023 and 2025: Other Operating Expenses jumped 7833.33% in 2023, then plunged 99.06% in 2025.
• A 5-year view of Other Operating Expenses shows it stood at $9000.0 in 2022, then surged by 7833.33% to $714000.0 in 2023, then climbed by 16.39% to $831000.0 in 2024, then slumped by 96.15% to $32000.0 in 2025, then jumped by 784.38% to $283000.0 in 2026.
• The last three Other Operating Expenses figures came in at $283000.0 (Q1 2026), $32000.0 (Q4 2025), and $11000.0 (Q3 2025), per Business Quant data.